Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines - Institut Pasteur Access content directly
Journal Articles Journal of Immunology Year : 2006

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

François Lemonnier

Abstract

Dendritic cell-derived exosomes (DEX) are nanomeric vesicles harboring MHC/peptide complexes capable of promoting primary T cell responses and tumor rejection in the presence of adjuvants. In this study, we show that, in the absence of adjuvants, DEX mediate potent Ag-dependent antitumor effects against preestablished tumors in mice pretreated with immunopotentiating dosing of cyclophosphamide. Cyclophosphamide could 1) abolish the suppressive function of CD4+CD25+Foxp3+ regulatory T cells, 2) markedly enhance the magnitude of secondary but not primary CTL responses induced by DEX vaccines, 3) synergize with DEX in therapy but not prophylaxis tumor models. Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of CD4+CD25+ regulatory T cells.

Dates and versions

pasteur-03360098 , version 1 (30-09-2021)

Identifiers

Cite

Julien Taieb, Nathalie Chaput, Noël Schartz, Stéphan Roux, Sophie Novault, et al.. Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. Journal of Immunology, 2006, 176 (5), pp.2722-2729. ⟨10.4049/jimmunol.176.5.2722⟩. ⟨pasteur-03360098⟩
18 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More